Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors
Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors
复制标题
DOI：
10.1016/j.leukres.2013.07.003
复制
发表时间：
2014-03-01
影响因子：
2.7
通讯作者：
Baccarani, Michele
中科院分区：
文献类型：
--
作者：
Efficace, Fabio;Rosti, Gianantonio;Baccarani, Michele
本研究的主要目的是概述175例慢性粒细胞白血病（CML）患者的关键特征，包括健康相关生活质量（HRQOL）和症状，这些患者报告了有意或无意的原因，未完全遵守伊马替尼治疗。意外组中男性比例显著较高（P = 0.037）。此外，该组患者平均年龄较低（P = 0.046）。报告故意原因的患者通常比报告非故意原因不依从的患者HRQOL更差，症状严重程度更高。这项研究表明，依从性不佳的患者不是一个同质的群体，因此不建议采用广义的方法来改善服药行为。(C)2013爱思唯尔有限公司保留所有权利。
The main objective of this study was to outline key characteristics, including health-related quality of life (HRQOL) and symptoms, in 175 chronic myeloid leukemia (CML) patients reporting intentional or unintentional reasons for not fully adhering to imatinib therapy. There was a significant higher proportion of males in the unintentional group (P = 0.037). Also, in this group patients were on average younger (P = 0.046). Patients reporting intentional reasons had generally a worse HRQOL profile and a higher symptom severity than those who reported unintentional reasons for non-adherence. This study suggests that patients with suboptimal adherence are not a homogenous group, thus generalized approaches to improve medication-taking behaviors are not recommended. (C) 2013 Elsevier Ltd. All rights reserved.